 HOUSTON, Aug. 19, 2021 PRNewswire -- Marker Therapeutics, Inc. Nasdaq:MRKR, a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company received notice of a Product Development Research award totaling approximately 13.1 million from the Cancer Prevention and Research Institute of Texas CPRIT to support the Companys Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401. The CPRIT award is intended to support the adjuvant arm of the Companys Phase 2 clinical trial evaluating MT-401 when given as an adjuvant therapy to patients with acute myeloid leukemia AML following a hematopoietic stem cell transplant. 